Exocrine pancreatic function in patients with progressive systemic sclerosis.
The exocrine pancreatic function was investigated in 16 patients with progressive systemic sclerosis by means of a meal test (Lundh test) and in 9 of the patients by the secretin-cholecystokinin test as well. Gastrointestinal involvement with progressive systemic sclerosis was evaluated by esophageal manometry and by routine roentgenographic series of the small bowel. Fecal fat excretion measurement, the D-xylose absorption test, and a small-intestinal biopsy procedure were carried out. Duodenal juice was cultured and bacterial counts were estimated. One-third of the patients had reduced exocrine pancreatic function, but only four patients had unequivocally a reduction that could be of clinical importance. The results obtained with the meal test were in accordance with the secretin-cholecystokinin test, indicating a preserved capacity for endogenous stimulation.
Hendel
L
L
Dept. of Dermatology, University of Copenhagen, Rigshospitalet, Denmark.
Worning
H
H
D000328:Adult; D000368:Aged; D000681:Amylases / Q000378:metabolism; D002766:Cholecystokinin / Q000008:administration & dosage; D004386:Duodenum / Q000201:enzymology / Q000382:microbiology; D005260:Female; D005502:Food; D005769:Gastrointestinal Motility; D006801:Humans; D007419:Intestinal Secretions / Q000201:enzymology / Q000382:microbiology; D008049:Lipase / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010179:Pancreas / Q000201:enzymology / Q000503:physiopathology*; D012595:Scleroderma, Systemic / Q000201:enzymology / Q000503:physiopathology*; D012633:Secretin / Q000008:administration & dosage
D012633:Secretin; D002766:Cholecystokinin; D008049:Lipase; D000681:Amylases